| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Beone Medicines AG (BEIGF) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 63 sells. BEIGF is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| VP | 85.0K | $1.86M | - | |
| CEO | 46.0K | $1.01M | -663,574 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 21, 2026 | Oyler John59 | Chief Executive Officer | Sale+OE | 109,713 | $315.28 | $34,590,855.40 | -45.6% | |
| Jul 17, 2026 | Oyler John59 | Chief Executive Officer | Sale+OE | 64,628 | $312.00 | $20,163,906.53 | -17.1% | |
| Jul 16, 2026 | Oyler John59 | Chief Executive Officer | Sale+OE | 283,154 | $315.56 | $89,351,597.71 | -20.2% | |
| Jul 14, 2026 | Oyler John59 | Chief Executive Officer | Sale+OE | 145,861 | $305.95 | $44,626,424.10 | -47.8% | |
| Jul 13, 2026 | Oyler John59 | Chief Executive Officer | Sale+OE | 60,218 | $303.18 | $18,256,807.71 | -28.6% | |
| Apr 8, 2026 | Lee Chan Henry47 | SVP, General Counsel | Sale+OE | 332 | $311.59 | $103,447.88 | -100% | |
| Mar 11, 2026 | Lee Chan Henry47 | SVP, General Counsel | Sale+OE | 341 | $300.00 | $102,300.00 | -100% |